Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Repeated Ketamine Infusions for Cognitive Impairment in Treatment-Resistant Bipolar Depression

EF 2022-23

Résumé
Bipolar disorder (BD) is a chronic psychiatric condition that consists of episodes of depression (bipolar depression) and mania or hypomania. Between 40-60% of patients with BD suffer from cognitive impairment even while they are not symptomatic. BD patients with cognitive impairment report poorer quality of life, more stress, and lower social and occupational functioning than patients with comparable mood symptoms and no cognitive impairment. Cognitive impairment in BD rarely responds to currently available BD treatments; thus, we are in dire need of new therapies to improve BD patients' functional recovery and quality of life. Intravenous (IV) ketamine has shown therapeutic potential for treatment-resistant bipolar depression (TRBD) as it rapidly reduces mood symptoms after just one dose. Additionally, preliminary studies have shown that ketamine may improve cognition in these patients. Therefore, the objective of this study is to investigate the potential procognitive effects of IV ketamine treatment for cognitive impairment in TRBD. In this phase II, randomized, placebo-controlled trial, participants diagnosed with TRBD are randomly assigned to receive either ketamine (0.5-0.75mg/kg over 40 minutes) or a placebo (midazolam). They receive four infusions over two weeks, and their cognitive functioning is assessed at baseline, two weeks, and four weeks. If the patients that receive ketamine demonstrate greater improvements in cognition than the placebo group, it will be a promising first step in discovering treatment options for BD patients with cognitive impairment and will help guide future research in this area.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486443
Name
Johnson Danica E
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Repeated Ketamine Infusions for Cognitive Impairment in Treatment-Resistant Bipolar Depression
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bipolar Depression; Bipolar Disorder; Cognitive Dysfunction; Cognitive Impairment; Ketamine; Pharmacotherapy; Procognitive Interventions; Psychiatric Disorders; Treatment Resistant
Abstract
Bipolar disorder (BD) is a chronic psychiatric condition that consists of episodes of depression (bipolar depression) and mania or hypomania. Between 40-60% of patients with BD suffer from cognitive impairment even while they are not symptomatic. BD patients with cognitive impairment report poorer quality of life, more stress, and lower social and occupational functioning than patients with comparable mood symptoms and no cognitive impairment. Cognitive impairment in BD rarely responds to currently available BD treatments; thus, we are in dire need of new therapies to improve BD patients' functional recovery and quality of life. Intravenous (IV) ketamine has shown therapeutic potential for treatment-resistant bipolar depression (TRBD) as it rapidly reduces mood symptoms after just one dose. Additionally, preliminary studies have shown that ketamine may improve cognition in these patients. Therefore, the objective of this study is to investigate the potential procognitive effects of IV ketamine treatment for cognitive impairment in TRBD. In this phase II, randomized, placebo-controlled trial, participants diagnosed with TRBD are randomly assigned to receive either ketamine (0.5-0.75mg/kg over 40 minutes) or a placebo (midazolam). They receive four infusions over two weeks, and their cognitive functioning is assessed at baseline, two weeks, and four weeks. If the patients that receive ketamine demonstrate greater improvements in cognition than the placebo group, it will be a promising first step in discovering treatment options for BD patients with cognitive impairment and will help guide future research in this area.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Johnson, Danica E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~